1. Home
  2. BVS vs STOK Comparison

BVS vs STOK Comparison

Compare BVS & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BVS
  • STOK
  • Stock Information
  • Founded
  • BVS 2011
  • STOK 2014
  • Country
  • BVS United States
  • STOK United States
  • Employees
  • BVS N/A
  • STOK N/A
  • Industry
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • STOK Biotechnology: Pharmaceutical Preparations
  • Sector
  • BVS Health Care
  • STOK Health Care
  • Exchange
  • BVS Nasdaq
  • STOK Nasdaq
  • Market Cap
  • BVS 883.7M
  • STOK 721.4M
  • IPO Year
  • BVS 2021
  • STOK 2019
  • Fundamental
  • Price
  • BVS $11.41
  • STOK $11.87
  • Analyst Decision
  • BVS Strong Buy
  • STOK Strong Buy
  • Analyst Count
  • BVS 3
  • STOK 7
  • Target Price
  • BVS $15.00
  • STOK $21.40
  • AVG Volume (30 Days)
  • BVS 297.3K
  • STOK 562.4K
  • Earning Date
  • BVS 11-05-2024
  • STOK 11-05-2024
  • Dividend Yield
  • BVS N/A
  • STOK N/A
  • EPS Growth
  • BVS N/A
  • STOK N/A
  • EPS
  • BVS N/A
  • STOK N/A
  • Revenue
  • BVS $555,061,000.00
  • STOK $16,742,999.00
  • Revenue This Year
  • BVS $11.24
  • STOK $103.04
  • Revenue Next Year
  • BVS $6.77
  • STOK N/A
  • P/E Ratio
  • BVS N/A
  • STOK N/A
  • Revenue Growth
  • BVS 10.40
  • STOK 81.08
  • 52 Week Low
  • BVS $3.90
  • STOK $4.09
  • 52 Week High
  • BVS $14.38
  • STOK $17.58
  • Technical
  • Relative Strength Index (RSI)
  • BVS 43.94
  • STOK 41.75
  • Support Level
  • BVS $10.95
  • STOK $11.80
  • Resistance Level
  • BVS $11.54
  • STOK $12.58
  • Average True Range (ATR)
  • BVS 0.48
  • STOK 0.83
  • MACD
  • BVS -0.04
  • STOK -0.06
  • Stochastic Oscillator
  • BVS 13.84
  • STOK 8.32

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Share on Social Networks: